| Description |
In a time of increasing product competition, restrictions on marketing activities, and limitations on promotion, the role of the Medical Science Liaison is becoming increasingly essential to the success of pharmaceutical, medical device and biotech companies. As the ranks of sales forces are diminishing and the drug development landscape changes, MSLs play a vital part in providing comprehensive field-based education to thought leaders on increasingly complex products. While a primary function is information dissemination, MSLs are also critical sources of competitive intelligence and help to inform research and development efforts, speaker recruitment, reimbursement and formulary decision-making. Now operating in an economic recession and an increasingly regulated environment, MSLs must take great care in affording maximum value in all activities they conduct.
Now in its fifth year, ExL Pharma’s MSL Best Practices covers topics that are of greatest consequence and meaning to MSLs, aimed at enhancing effectiveness in field-based and office-based activities. The experienced speaking faculty, with fresh and insightful perspectives, equips MSLs with new tools for bringing optimal value to the KOL, company and industry as a whole, while remaining personally fulfilled in their positions. The agenda offers tracks that are tailored to meet the needs of both new and experienced MSLs, and prepares teams for the changing dynamics of industry-KOL interactions. This highly interactive and informative event is one that cannot be missed!
This event is co-located this year with ExL Pharma’s 10th Investigator Initiated Trials Conference!
Who should Attend
Company Type
* Pharmaceutical
* Biotech
* Medical Device
Departments
* Medical Science Liaisons (MSLS, MLs)
* Medical Affairs
* Medical Communications
* Scientific Affairs
* Clinical Trial Liaisons
* Clinical Research
* Medical Education
* Clinical/Outcomes Liaisons
* Clinical Investigators
* KOL Development
* Business Intelligence
* Regulatory Affairs
* Marketing
|
|
